Opexa Therapeutics (OPXA) Misses Q3 EPS by 3c

November 14, 2016 7:37 AM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Opexa Therapeutics (NASDAQ: OPXA) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $726.3 thousand versus the consensus estimate of $720 thousand.

Cash and cash equivalents were $5,814,300 as of September 30, 2016, compared to $12,583,764 as of December 31, 2015. As of September 30, 2016, the Company had accounts payable and accrued expenses of $2,121,043.

For earnings history and earnings-related data on Opexa Therapeutics (OPXA) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment